Abstract
Background and Objective: Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide. Genotoxic stress resistance in patients often contributes to poor clinical outcomes, and is intensively associated to the upregulation of Nrf2/ARE signaling pathway. In this study, we examined the connection between the anticancer activity of two novel indazolo[3,2-b]quinazolinone (IQ) derivatives, IQ-7 and IQ-12, and their effect on the Nrf2/ARE signaling pathway.
Methods: We initially measured the cytotoxicity of IQ-7 and IQ-12 in Hep3B (human hepatoma cell) and HL-7702 (normal human liver cell) cell lines, then further detected their effects on Nrf2/ARE signaling pathway and apoptosis. Results: IQ-7 and IQ-12 downregulated the expression levels of Nrf2 and its downstream target genes, such as NQO1, HO-1 and Gclc. In Hep3B cells treated with IQ-7 or IQ-12, the mitochondrial membrane potential decreased dramatically while the expression level of the pro-apoptotic protein VDAC1 and anti-apoptotic protein Bcl-2 significantly increased and decreased, respectively. In addition, IQ-7 (but not IQ-12) also induced the activity of Caspase-3. Interestingly, IQ-7 appeared to selectively inhibit Hep3B cells while having rare adverse effect on HL-7702 cells. Conclusion: The two compounds were shown to induce apoptosis and inhibit the Nrf2/ARE signaling pathway in Hep3B cells, and IQ-7 was suggested a degree of specificity against cancer cells. The design of these compounds may therefore represent a new strategy for designing quinazoline derivatives that could selectively target carcinoma cells.Keywords: Quinazoline, quinazolinone, Nrf2, hepatocellular carcinoma, apoptosis.
Current Molecular Medicine
Title:Indazolo[3,2-b]quinazolinones Attack Hepatocellular Carcinoma Hep3B Cells by Inducing Mitochondrial-Dependent Apoptosis and Inhibition of Nrf2/ARE Signaling Pathway
Volume: 16 Issue: 9
Author(s): Y. Zhang, R. Qiao, D. He, Z. Zhao, S. Yang, H. Zou, X. Zhang, M. Wu, J. Chen and P. Chen
Affiliation:
Keywords: Quinazoline, quinazolinone, Nrf2, hepatocellular carcinoma, apoptosis.
Abstract: Background and Objective: Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide. Genotoxic stress resistance in patients often contributes to poor clinical outcomes, and is intensively associated to the upregulation of Nrf2/ARE signaling pathway. In this study, we examined the connection between the anticancer activity of two novel indazolo[3,2-b]quinazolinone (IQ) derivatives, IQ-7 and IQ-12, and their effect on the Nrf2/ARE signaling pathway.
Methods: We initially measured the cytotoxicity of IQ-7 and IQ-12 in Hep3B (human hepatoma cell) and HL-7702 (normal human liver cell) cell lines, then further detected their effects on Nrf2/ARE signaling pathway and apoptosis. Results: IQ-7 and IQ-12 downregulated the expression levels of Nrf2 and its downstream target genes, such as NQO1, HO-1 and Gclc. In Hep3B cells treated with IQ-7 or IQ-12, the mitochondrial membrane potential decreased dramatically while the expression level of the pro-apoptotic protein VDAC1 and anti-apoptotic protein Bcl-2 significantly increased and decreased, respectively. In addition, IQ-7 (but not IQ-12) also induced the activity of Caspase-3. Interestingly, IQ-7 appeared to selectively inhibit Hep3B cells while having rare adverse effect on HL-7702 cells. Conclusion: The two compounds were shown to induce apoptosis and inhibit the Nrf2/ARE signaling pathway in Hep3B cells, and IQ-7 was suggested a degree of specificity against cancer cells. The design of these compounds may therefore represent a new strategy for designing quinazoline derivatives that could selectively target carcinoma cells.Export Options
About this article
Cite this article as:
Zhang Y., Qiao R., He D., Zhao Z., Yang S., Zou H., Zhang X., Wu M., Chen J. and Chen P., Indazolo[3,2-b]quinazolinones Attack Hepatocellular Carcinoma Hep3B Cells by Inducing Mitochondrial-Dependent Apoptosis and Inhibition of Nrf2/ARE Signaling Pathway, Current Molecular Medicine 2016; 16 (9) . https://dx.doi.org/10.2174/1566524016666161128114444
DOI https://dx.doi.org/10.2174/1566524016666161128114444 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
Call for Papers in Thematic Issues
Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders
Vertigo and vestibular diseases are common among middle-aged and older adults, significantly increasing the risk of falls and leading to injuries and disabilities. Despite their prevalence, therapeutic advancements are hindered by a limited understanding of the underlying molecular and cellular mechanisms. This Special Issue is dedicated to bridging this gap ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effect of Melatonin on Superoxide Dismutase and Glutathione Peroxidase Activity, and Malondialdehyde Levels in the Targeted and the Non-targeted Lung and Heart Tissues after Irradiation in Xenograft Mice Colon Cancer
Current Molecular Pharmacology The Promise of miRNA Replacement Therapy for Hepatocellular Carcinoma
Current Gene Therapy Recent Advances on Epidermal Growth Factor Receptor as a Molecular Target for Breast Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry In Vivo Monitoring of Cell Based Therapy in the Liver
Current Molecular Imaging (Discontinued) Novel Immunotherapeutic Strategies for Invasive Fungal Disease
Current Drug Targets - Cardiovascular & Hematological Disorders FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Role of Prolyl Isomerase Pin1 in Pathogenesis of Diseases and Remedy for the Diseases from Natural Products
Current Drug Targets Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic:Part-II Imaging and Treatment of Oncological Diseases (Guest Editor: J.F.W. Nijsen) ]
Anti-Cancer Agents in Medicinal Chemistry The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design Serotonin (5HTR2A and 5HTR3A) and GABA (GABAB) Receptor Genes Overexpression are Correlated with Non-small Cell Lung Cancer (NSCLC)
Current Cancer Therapy Reviews In Vitro Studies of Water-Stable Cationic Carbosilane Dendrimers As Delivery Vehicles for Gene Therapy Against HIV and Hepatocarcinoma
Current Medicinal Chemistry From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism Metaboloepigenetics: The Emerging Network in Stem Cell Homeostasis Regulation
Current Stem Cell Research & Therapy Immunoliposomes in Acute Myeloid Leukaemia Therapy: An Overview of Possible Targets and Obstacles
Current Medicinal Chemistry Modulation of Cellular Response to Anticancer Treatment by Caffeine: Inhibition of Cell Cycle Checkpoints, DNA Repair and More
Current Pharmaceutical Biotechnology Prediction of Cancer Rescue p53 Mutants In Silico Using Naïve Bayes Learning Methodology
Protein & Peptide Letters Synthesis, Molecular Docking and Anticancer Evaluation of New Arylazothiazoles
Current Organic Synthesis Translational Theragnosis of Ovarian Cancer: where do we stand?
Current Medicinal Chemistry The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry